デフォルト表紙
市場調査レポート
商品コード
1072737

PARP阻害剤による癌治療の世界市場および臨床試験に関する洞察:2028年

Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028

出版日: | 発行: KuicK Research | ページ情報: 英文 4000 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.28円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

PARP阻害剤による癌治療の世界市場および臨床試験に関する洞察:2028年
出版日: 2022年05月01日
発行: KuicK Research
ページ情報: 英文 4000 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要
当レポートでは、世界のPARP阻害剤による癌治療市場について調査し、市場の概要とともに、将来の市場見通し、地域別動向、参入企業の競合情勢などを提供しています。

目次

第1章 ポリ(ADP-リボース)ポリメラーゼ阻害剤のイントロダクション

第2章 PARPタンパク質:癌治療薬を開発するための魅力的なターゲット

  • PARP阻害剤の標的部位の構造的構成
  • PARP阻害剤の構造的構成

第3章 正常細胞および癌細胞におけるPARPタンパク質の役割の治療的利用

  • 正常細胞におけるPARPタンパク質の重要性
  • 腫瘍形成におけるPARPタンパク質の重要性:細胞分裂とDNAへの影響

修復

  • PARP阻害剤:癌細胞を排除するための異なる作用機序

第4章 世界のPARP阻害剤市場の見通し

  • 現在の市場シナリオ
  • 将来の市場機会

第5章 PARP阻害剤市場の機会、地域別

  • 米国
  • 欧州
  • 中国
  • 日本

第6章 オラパリブ(リンパルザ)-最初に承認されたPARP阻害剤:2014年

  • 概要
  • 特許の独占性
  • 価格と投与量
  • 売上分析

第7章 ルカパリブ(ルブラカ)-2番目に承認されたPARP阻害剤:2016年

  • 概要
  • 特許の独占性
  • 価格と投与量
  • 売上分析

第8章 ニラパリブ(ゼジュラ)-3番目に承認されたPAPR阻害剤:2017年

  • 概要
  • 特許の独占性
  • 価格と投与量
  • 売上分析

第9章 タラゾパリブ(タルゼンナ)-4番目に承認されたPARP阻害剤:2018年

  • 概要
  • 特許の独占性
  • 価格と投与量

第10章 フズロパリブ(AiRuiYi)-5番目に承認されたPARP阻害剤:2020年

第11章 パミパリブ(Partruvix)-6番目に承認されたPARP阻害剤:2021年

第12章 PARP阻害剤-2028年までの売上予測

  • リンパルザ
  • ルブラカ
  • ゼジュラ
  • タルゼンナ

第13章 承認されたPARP阻害剤の償還方針

第14章 PARP阻害剤の臨床試験の洞察

第15章 世界のポリ(ADP-リボース)ポリメラーゼ阻害剤の臨床試験、企業別、適応別、相別

  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第16章 市販のポリ(ADP-リボース)ポリメラーゼ阻害剤の臨床的洞察

第17章 従来の癌治療別PARP阻害剤:有効性と投与量の分析

  • 化学療法を伴うPARP阻害剤
  • 放射線療法と併用するPARP阻害剤

第18章 PARP阻害剤の有効性の改善、現代の癌治療別

  • PARP阻害剤と標的療法の組み合わせ
  • 免疫療法と併用するPARP阻害剤

第19章 世界のPARP阻害剤市場力学

  • 促進要因
  • 市場の課題

第20章 PARP阻害剤市場の将来展望

第21章 競合情勢

  • 2X Oncology
  • Abott Laboratories
  • Allarity Therapeutics
  • AstraZeneca
  • BeiGene
  • Bristol Myers Squibb
  • Cephalon
  • Clovis Oncology
  • Eisai Co. Ltd
  • GlaxoSmithKline
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals
  • KuDOS Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lead Therapeutics
  • Ono Pharmaceutical
  • Pfizer
図表
  • Figure 1-1: Biochemistry & Biological Functions of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes
  • Figure 1-2: History & Evolution of PARP Inhibitors
  • Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes
  • Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism
  • Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells
  • Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment
  • Figure 4-1: Global - Cancer Incidences & Deaths (Million), 2020
  • Figure 4-2: Global - PARP Inhibitor Market Size (US$ Million), 2017-2021
  • Figure 4-3: Global - PARP Inhibitor Market by Drug Type (US$ Million), 2021
  • Figure 4-4: Global - PARP Inhibitor Market by Drug Type (US$ Million), 2020
  • Figure 4-5: Global - PARP Inhibitor Market by Drug Type (%), 2021
  • Figure 4-6: Global - PARP Inhibitor Market by Drug Type (%), 2020
  • Figure 4-7: Global - PARP Inhibitor Market Size (US$ Billion), 2022 - 2028
  • Figure 5-1: US - Cancer Incidences & Deaths (Million), 2020 & 2030
  • Figure 5-2: US - PARP Inhibitor Market Size (US$ Million), 2020 & 2021
  • Figure 5-3: US vs. ROW - PARP Inhibitor Market Size (US$ Million), 2021
  • Figure 5-4: US vs. ROW - PARP Inhibitor Market Size (%), 2021
  • Figure 5-5: US - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 5-6: Europe - Cancer Incidences & Deaths (Million), 2020 & 2030
  • Figure 5-7: Europe - PARP Inhibitor Market Size (US$ Million), 2020 & 2021
  • Figure 5-8: Europe vs. ROW - PARP Inhibitor Market Size (US$ Million), 2021
  • Figure 5-9: Europe vs. ROW - PARP Inhibitor Market Size (%), 2021
  • Figure 5-10: Europe - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 5-11: China - Cancer Incidences & Deaths (Million), 2020 & 2030
  • Figure 5-12: China - PARP Inhibitor Market Size (US$ Million), 2020 & 2021
  • Figure 5-13: China vs. ROW - PARP Inhibitor Market Size (US$ Million), 2021
  • Figure 5-14: China vs. ROW - PARP Inhibitor Market Size (%), 2021
  • Figure 5-15: China - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 5-16: Japan - Cancer Incidences & Deaths (Million), 2020 & 2030
  • Figure 5-17: Japan - PARP Inhibitor Market Size (US$ Million), 2020 & 2021
  • Figure 5-18: Japan - PARP Inhibitor Market Size (US$ Million), 2022 - 2028
  • Figure 6-1: US - Olaparib FDA Orphan Designation Year by Indication
  • Figure 6-2: US - Lynparza FDA Approval Year by Indication
  • Figure 6-3: Europe - Lynparza EMA Year by Indication
  • Figure 6-4: Lynparza - Initial Approval Year by Region
  • Figure 6-5: US - Lynparza Patent by Assignee
  • Figure 6-6: US - Lynparza Patent Approval & Expiration Year
  • Figure 6-7: Lynparza - Patent Exclusivity Year by Region
  • Figure 6-8: US - Cost of Supply of 60 Tablets & Per Unit Cost of Lynparza Oral Tablet (US$), May'2022
  • Figure 6-9: US - Cost of Supply of 120 Tablets & Per Unit Cost of Lynparza Oral Tablet (US$), May'2022
  • Figure 6-10: UK - Cost of Supply of 56 Tablets & Per Unit Cost of Lynparza Oral Tablet (GBP/US$), May'2022
  • Figure 6-11: Lynparza - Recommended Initial & Dose Reductions (mg/day)
  • Figure 6-12: Lynparza - Cost of Daily & Annual Cost of Treatment (US$), May'2022
  • Figure 6-13: Global - Lynparza Annual Sales (US$ Million), 2018 - 2021
  • Figure 6-14: US - Lynparza Annual Sales (US$ Million), 2018 - 2021
  • Figure 6-15: Europe - Lynparza Annual Sales (US$ Million), 2018 - 2021
  • Figure 6-16: ROW - Lynparza Annual Sales (US$ Million), 2018 - 2021
  • Figure 6-17: Lynparza - Annual Sales by Region (US$ Million), 2021
  • Figure 6-18: Lynparza - Annual Sales by Region (%), 2021
  • Figure 6-19: Global - Lynparza Quarterly Sales (US$ Million), 2021
  • Figure 6-20: Global - Lynparza Quarterly Sales (US$ Million), 2020
  • Figure 7-1: US - Rucaparib FDA Orphan Designation & Patent Exclusivity Year
  • Figure 7-2: US - Rubraca FDA Approval Year by Indication
  • Figure 7-3: Rubraca - Approval Year by Region
  • Figure 7-4: US - Lynparza Patent Approval & Expiration Year
  • Figure 7-5: US - Cost of Supply of 60 Tablets & Per Unit Cost of Rubraca Oral Tablet (US$), May'2022
  • Figure 7-6: Europe - Cost of Supply of 60 Tablets & Per Unit Cost of Rubraca 200mg Oral Tablet (Euro/US$), May'2022
  • Figure 7-7: Europe - Cost of Supply of 60 Tablets & Per Unit Cost of Rubraca 300mg Oral Tablet (Euro/US$), May'2022
  • Figure 7-8: Rubraca - Recommended Initial & Dose Reductions (mg/day)
  • Figure 7-9: Rubraca - Recommended Maximum & Minimum Dose (mg/day)
  • Figure 7-10: Rubraca - Cost of Daily & Annual Cost of Treatment (US$), May'2022
  • Figure 7-11: Global - Rubraca Annual Sales (US$ Million), 2018 - 2021
  • Figure 7-12: US - Rubraca Annual Sales (US$ Million), 2018 - 2021
  • Figure 7-13: Europe - Rubraca Annual Sales (US$ Million), 2019 - 2021
  • Figure 7-14: Rubraca - Annual Sales by Region (US$ Million), 2021
  • Figure 7-15: Rubraca - Annual Sales by Region (%), 2021
  • Figure 7-16: Rubraca - Annual Sales by Region (US$ Million), 2020
  • Figure 7-17: Rubraca - Annual Sales by Region (%), 2021
  • Figure 7-18: Global - Rubraca Quarterly Sales (US$ Million), 2021
  • Figure 7-19: US - Rubraca Quarterly Sales (US$ Million), 2021
  • Figure 7-20: Europe - Rubraca Quarterly Sales (US$ Million), 2021
  • Figure 8-1: US - Niraparib FDA Orphan Designation & Patent Exclusivity Year
  • Figure 8-2: US - Zejula FDA Approval Year by Ovarian Cancer Subtypes
  • Figure 8-3: Zejula - Initial Approval Year by Region
  • Figure 8-4: US - Zejula Patent Approval & Expiration Year
  • Figure 8-5: China - Zejula Patent Expiration Year
  • Figure 8-6: US - Cost of Supply of 30 Capsules & Per Unit Cost of Zejula Oral Capsules (US$), May'2022
  • Figure 8-7: US - Cost of Supply of 90 Capsules & Per Unit Cost of Zejula Oral Capsules (US$), May'2022
  • Figure 8-8: UK - Cost of Supply of 84, 56 Capsules & Per Unit Cost of Zejula Oral Capsule (GBP/US$), May'2022
  • Figure 8-9: Zejula - Recommended Initial Dose by Weight (mg/day)
  • Figure 8-10: Zejula - Recommended Initial & Dose Reductions (mg/day)
  • Figure 8-11: Zejula - Recommended Maximum & Minimum Dose (mg/day)
  • Figure 8-12: Zejula - Cost of Daily & Annual Cost of Treatment (US$), May'2022
  • Figure 8-13: Global - Zejula Annual Sales (Euro/US$ Million), 2019 - 2021
  • Figure 8-14: US - Zejula Annual Sales (Euro/US$ Million), 2019 - 2021
  • Figure 8-15: Europe - Zejula Annual Sales (Euro/US$ Million), 2019 - 2021
  • Figure 8-16: ROW - Zejula Annual Sales (Euro/US$ Million), 2020 & 2021
  • Figure 8-17: Zejula - Annual Sales by Region (Euro/US$ Million), 2021
  • Figure 8-18: Zejula - Annual Sales by Region (%), 2021
  • Figure 8-19: Global - Zejula Quarterly Sales (Euro/US$ Million), 2021
  • Figure 8-20: US - Zejula Quarterly Sales (Euro/US$ Million), 2021
  • Figure 8-21: ROW - Zejula Quarterly Sales (Euro/US$ Million), 2021
  • Figure 9-1: Talzenna - Approval Year by Region
  • Figure 9-2: US - Talzenna Patent Approval & Expiration Year
  • Figure 9-3: US - Talzenna Patent by Assignee
  • Figure 9-4: US - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 0.25mg Oral Capsules (US$), May'2022
  • Figure 9-5: US - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 0.5mg, 0.75mg, & 1mg Oral Capsules (US$), May'2022
  • Figure 9-6: UK - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 0.25mg Oral Capsule (GBP/US$), May'2022
  • Figure 9-7: UK - Cost of Supply of 30 Capsules & Per Unit Cost of Talzenna 1mg Oral Capsule (GBP/US$), May'2022
  • Figure 9-8: Talzenna - Recommended Initial & Dose Reductions (mg/day)
  • Figure 9-9: Talzenna - Recommended Maximum & Minimum Dose (mg/day)
  • Figure 9-10: Talzenna - Cost of Daily & Annual Cost of Treatment (US$), May'2022
  • Figure 10-1: Fuzuloparib - Recommended Maximum & Minimum Dose (mg/day)
  • Figure 11-1: China - Partruvix Priority Review & NMPA Approval Year
  • Figure 12-1: Global - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-2: US - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-3: Europe - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-4: ROW - Lynparza Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-5: Global - Rubraca Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-6: US - Rubraca Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-7: Europe - Rubraca Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-8: Global - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-9: US - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-10: Europe - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-11: ROW - Zejula Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 12-12: Global - Talzenna Estimated Sales Value (US$ Million), 2022 - 2028
  • Figure 13-1: Lynparza - Total Treatment Cost & Reimbursement Cost (US$)
  • Figure 13-2: Lynparza - In Pocket & Out of Pocket Cost of Treatment (%)
  • Figure 13-3: Rubraca - Total Treatment Cost & Reimbursement Cost (US$)
  • Figure 13-4: Rubraca - In Pocket & Out of Pocket Cost of Treatment (%)
  • Figure 13-5: Zejula - Total Treatment Cost & Reimbursement Cost (US$)
  • Figure 13-6: Zejula - In Pocket & Out of Pocket Cost of Treatment (%)
  • Figure 13-7: Zejula - Total Treatment Cost & Reimbursement Cost (US$)
  • Figure 13-8: Zejula - In Pocket & Out of Pocket Cost of Treatment (%)
  • Figure 14-1: Global - PARP Inhibitor Drugs in Clinical Trials by Company, 2022 till 2028
  • Figure 14-2: Global - PARP Inhibitor Drugs in Clinical Trials by Country, 2022 till 2028
  • Figure 14-3: Global - PARP Inhibitor Drugs in Clinical Trials by Indication, 2022 till 2028
  • Figure 14-4: Global - PARP Inhibitor Drugs in Clinical Trials by Phase, 2022 till 2028
  • Figure 17-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m2)
  • Figure 17-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
  • Figure 17-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US$/Cycle)
  • Figure 17-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m2/Day)
  • Figure 17-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administration/Cycle)
  • Figure 17-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US$/Cycle)
  • Figure 17-7: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine & Carboplatin Chemotherapy vs. Combination Therapy with Iniparib (Months)
目次

Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 Report Highlights:

  • Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
  • Commercially Available PARP inhibitors: > 5 Drugs
  • Comprehensive Clinical Insight On More Than 35 PARP Drug In Clinical Trials
  • Global PARP Clinical Trials Insight by Company, Country, Indication & Phase
  • Market Indicators Till 2028
  • Approved Drugs Dosage, Sales, Patent, Price Insight
  • Approved Drugs Sales Forecast Till 2028
  • Global & Regional Market Analysis
  • Regional Analysis Based On Drug Approvals: US, Europe, Chna & Japan

Genomic studies have revealed that altered DNA damage response (DDR) is an emerging hallmark and enabling characteristic of cancer, associated with both tumor initiation and progression. In addition, as anti-cancer cytotoxic agents such as chemotherapy and radiation function to induce DNA damage in cancer cells, alterations in DDR have role in resistance to these therapies. Therefore, scientists believed that targeting of DDR will significantly improve treatment and survival of cancer patients. One prominent DDR family of proteins which is being investigated is poly (ADP-ribose) polymerase (PARP) enzymes which have emerged as potential therapeutic target for the management of cancer.

Scientists have developed several PARP inhibitors which work by binding to the catalytic domain of the PARP enzyme. PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) are currently approved as a monotherapy by US FDA and EMA. Currently marketed PARP Inhibitors are approved for treating breast cancer, ovarian cancer, fallopian tube cancer; primary peritoneal cancer, and pancreatic cancer. In addition to this, a large number of PARP inhibitors are present in clinical development which is expected to gain approval during the forecast period.

For instance, Senaparib (IMP4297) developed by Impact Therapeutics is an investigational agent which works by targeting PARP (poly-ADP ribose polymerase). The company is currently conducting two phase-1 trials of senaparib in China and Australia. Till date, about 100 patients have been treated with Senaparib and initial results have demonstrated encouraging response. In comparison to other PARP inhibitors currently on the market and in clinical trials; senaparib has a wider therapeutic window and a better safety profile. This potentially makes senaparib more suitable for patients taking the drug chronically such as in maintenance therapy. Moreover, researchers believed that the combination of senaparib with other cancer targeting agents will also demonstrate promising results. Therefore, senaparib has the potential to be the best-in-class PARP inhibitor in the forthcoming years.

Apart from its role as monotherapy, PARP inhibitors have also shown to be promising in combination with other therapeutics including immunotherapy, PI3K, MEK and CDK 4/6 inhibitors. Furthermore, studies have revealed that combining PARP inhibitors with DNA damaging agents including chemotherapy and radiotherapy could prevent repair of treatment induced damage. These approaches have been widely investigated in ovarian and breast cancer. The coming years is expected to witness dominance of combinational therapy in PARP inhibitors market owing to its enhanced efficacy, specificity, and targetability in the management of wide range of cancers.

As per our report findings, the global PARP inhibitor market is expected to surpass US$ 6 Billion by 2028. Several factors including rising geriatric population with increased risk of developing cancer, increasing emphasis on research and development, and large number of ongoing clinical trials are the major factors boosting the growth of market. Further, favorable government policies for life science companies and government funding are also expected to boost the PARP inhibitor therapy demand in near future.

The Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 report is a comprehensive analysis of a variety of factors that are prevalent in the PARP Inhibitors. The report provides in-depth analysis on the globally approved PARP inhibitors along with their patent expiration, pricing, dosage, sales analysis, and forecast. It also gives a detailed description of drivers and opportunities in PARP Inhibitor market that helps the consumers and potential customers to get a clear vision and take effective decisions. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

Table of Contents

1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors

  • 1.1 PARP Inhibitors as Unique Cancer Therapy
  • 1.2 Evolutionary Aspects of PARP Inhibitors

2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics

  • 2.1 Structural Organization of Target Site of PARP Inhibitors
  • 2.2 Structural Organization of PARP Inhibitors

3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells & Cancer Cells

  • 3.1 Significance of PARP Proteins in Normal Cells
  • 3.2 Significance of PARP Proteins in Tumorgenesis: Affecting Cell Division & DNA

Repair

  • 3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. Global PARP Inhibitor Market Outlook

  • 4.1 Current Market Scenario
  • 4.2 Future Market Opportunity

5. PARP Inhibitor Market Opportunity by Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 China
  • 5.4 Japan

6. Olaparib (Lynparza) - 1st Approved PARP Inhibitor; 2014

  • 6.1 Overview
  • 6.2 Patent Exclusivity
  • 6.3 Pricing & Dosage
  • 6.4 Sales Analysis

7. Rucaparib (Rubraca) - 2nd Approved PARP Inhibitor; 2016

  • 7.1 Overview
  • 7.2 Patent Exclusivity
  • 7.3 Pricing & Dosage
  • 7.4 Sales Analysis

8. Niraparib (Zejula) - 3rd Approved PAPR Inhibitor; 2017

  • 8.1 Overview
  • 8.2 Patent Exclusivity
  • 8.3 Pricing & Dosage
  • 8.4 Sales Analysis

9. Talazoparib (Talzenna) - 4th Approved PARP Inhibitor; 2018

  • 9.1 Overview
  • 9.2 Patent Exclusivity
  • 9.3 Pricing & Dosage

10. Fuzuloparib (AiRuiYi) - 5th Approved PARP Inhibitor; 2020

11. Pamiparib (Partruvix) - 6th Approved PARP Inhibitor; 2021

12. PARP Inhibitors - Sales Forecast Till 2028

  • 12.1 Lynparza
  • 12.2 Rubraca
  • 12.3 Zejula
  • 12.4 Talzenna

13. Approved PARP Inhibitors Reimbursement Policy

  • 13.1 Lynparza Reimbursement Policy
  • 13.2 Rubraca Reimbursement Policy
  • 13.3 Zejula Reimbursement Policy
  • 13.4 Talzenna Reimbursement Policy

14. PARP Inhibitor Clinical Trial Insight

  • 14.1 Company
  • 14.2 Country
  • 14.3 Indication
  • 14.4 Indication

15. Global Poly(ADP-Ribose) Polymerase Inhibitors Clinical Trials By Company, Indication & Phase

  • 15.1 Preclinical
  • 15.2 Phase-I
  • 15.3 Phase-I/II
  • 15.4 Phase-II
  • 15.5 Phase-II/III
  • 15.6 Phase-III

16. Marketed Poly(ADP-Ribose) Polymerase Inhibitors Clinical insights

17. PARP Inhibitors with Conventional Cancer Therapy: Efficacy & Dosage Analysis

  • 17.1 PARP Inhibitors with Chemotherapy
    • 17.1.1 Temozolomide
    • 17.1.2 Platinum Salts
    • 17.1.3 Taxanes
    • 17.1.4 Gemcitabine
    • 17.1.5 Topoisomerase Iinhibitors
  • 17.2 PARP Inhibitors in Combination with Radiotherapy

18. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies

  • 18.1 Combination of PARP Inhibitors & Targeted Therapies
    • 18.1.1 PARP Inhibitors with EGFR Inhibitors
    • 18.1.2 PARP Inhibitors with VEGFR Inhibitors
    • 18.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
    • 18.1.4 PARP Inhibitors with Trastuzumab
    • 18.1.5 Anti-endocrine agents
    • 18.1.6 HSP90 Inhibitors
    • 18.1.7 IGF-1R & HDAC Inhibitors
  • 18.2 PARP Inhibitors in Combination with Immunotherapies

19. Global PARP Inhibitors Market Dynamics

  • 19.1 Drivers
  • 19.2 Market Challenges

20. PARP Inhibitor Market Future Perspective

21. Competitive Landscape

  • 21.1 2X Oncology
  • 21.2 Abott Laboratories
  • 21.3 Allarity Therapeutics
  • 21.4 AstraZeneca
  • 21.5 BeiGene
  • 21.6 Bristol Myers Squibb
  • 21.7 Cephalon
  • 21.8 Clovis Oncology
  • 21.9 Eisai Co. Ltd
  • 21.10 GlaxoSmithKline
  • 21.11 IMPACT Therapeutics
  • 21.12 Jeil Pharmaceuticals
  • 21.13 KuDOS Pharmaceuticals
  • 21.14 Kyowa Hakko Kirin
  • 21.15 Lead Therapeutics
  • 21.16 Ono Pharmaceutical
  • 21.17 Pfizer